Survival analysis of veteran patients with pancreatic cancer

David Kim, Hong Zhu, Ammar Nassri, Ali Mokdad, Sachin Kukreja, Patricio Polanco, Sergio Huerta, Zeeshan Ramzan

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: For patients with pancreatic cancer, the identification of reliable predictors of their outcomes could be invaluable for directing the managements. This study aimed to identify clinical and laboratory factors that could be used to predict early (≤6 months) or late (>6 months) mortality. Methods: Medical records of patients diagnosed with pancreatic cancer in the VA North Texas Health Care System from 2005 to 2010 were retrospectively reviewed. Univariate and multivariate analyses (MVA) were performed and the utility of cancer antigen 19-9 (CA19-9) test was explored. Results: Altogether 109 patients with pancreatic cancer, 89.0% of whom were with adenocarcinoma, were divided into early (n = 62) and late (n = 47) mortality groups. Kaplan–Meier analysis revealed a median survival of 154 days [95% confidence interval (CI) 93–194 days]. On MVA, abdominal pain (OR = 10.6, P = 0.009) and large tumor size (OR = 2.4, P = 0.028) were significantly associated with early mortality, while palliative chemotherapy (OR = 0.048, P = 0.001) and neuroendocrine tumor (OR = 0.009, P = 0.024) were significantly associated with late mortality. Subgroup analyses of adenocarcinoma and late-stage patients revealed similar results. Serum CA19-9 performed poorly as a prognostic indicator in both groups (P = 0.43), in metastatic disease at diagnosis (P = 0.32) and after treatment (P = 0.65). Conclusions: Abdominal pain and large tumor size portends a poor prognosis in patients with pancreatic cancer. Palliative chemotherapy and surgical intervention may prolong the patient's survival. CA19-9 is not universally reliable for predicting metastasis, survival, or the responses to chemotherapy.

Original languageEnglish (US)
Pages (from-to)399-407
Number of pages9
JournalJournal of Digestive Diseases
Volume17
Issue number6
DOIs
StatePublished - Jun 1 2016

Fingerprint

Veterans
Survival Analysis
Pancreatic Neoplasms
Mortality
Neoplasms
Antigens
Drug Therapy
Abdominal Pain
Survival
Adenocarcinoma
Multivariate Analysis
Neuroendocrine Tumors
Medical Records
Confidence Intervals
Neoplasm Metastasis
Delivery of Health Care
Serum

Keywords

  • CA19-9 antigen
  • pancreatic adenocarcinoma
  • pancreatic neoplasms
  • predictor of mortality
  • veteran

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Survival analysis of veteran patients with pancreatic cancer. / Kim, David; Zhu, Hong; Nassri, Ammar; Mokdad, Ali; Kukreja, Sachin; Polanco, Patricio; Huerta, Sergio; Ramzan, Zeeshan.

In: Journal of Digestive Diseases, Vol. 17, No. 6, 01.06.2016, p. 399-407.

Research output: Contribution to journalArticle

Kim, David ; Zhu, Hong ; Nassri, Ammar ; Mokdad, Ali ; Kukreja, Sachin ; Polanco, Patricio ; Huerta, Sergio ; Ramzan, Zeeshan. / Survival analysis of veteran patients with pancreatic cancer. In: Journal of Digestive Diseases. 2016 ; Vol. 17, No. 6. pp. 399-407.
@article{036cbb5829b74819a709c3347c452fec,
title = "Survival analysis of veteran patients with pancreatic cancer",
abstract = "Objective: For patients with pancreatic cancer, the identification of reliable predictors of their outcomes could be invaluable for directing the managements. This study aimed to identify clinical and laboratory factors that could be used to predict early (≤6 months) or late (>6 months) mortality. Methods: Medical records of patients diagnosed with pancreatic cancer in the VA North Texas Health Care System from 2005 to 2010 were retrospectively reviewed. Univariate and multivariate analyses (MVA) were performed and the utility of cancer antigen 19-9 (CA19-9) test was explored. Results: Altogether 109 patients with pancreatic cancer, 89.0{\%} of whom were with adenocarcinoma, were divided into early (n = 62) and late (n = 47) mortality groups. Kaplan–Meier analysis revealed a median survival of 154 days [95{\%} confidence interval (CI) 93–194 days]. On MVA, abdominal pain (OR = 10.6, P = 0.009) and large tumor size (OR = 2.4, P = 0.028) were significantly associated with early mortality, while palliative chemotherapy (OR = 0.048, P = 0.001) and neuroendocrine tumor (OR = 0.009, P = 0.024) were significantly associated with late mortality. Subgroup analyses of adenocarcinoma and late-stage patients revealed similar results. Serum CA19-9 performed poorly as a prognostic indicator in both groups (P = 0.43), in metastatic disease at diagnosis (P = 0.32) and after treatment (P = 0.65). Conclusions: Abdominal pain and large tumor size portends a poor prognosis in patients with pancreatic cancer. Palliative chemotherapy and surgical intervention may prolong the patient's survival. CA19-9 is not universally reliable for predicting metastasis, survival, or the responses to chemotherapy.",
keywords = "CA19-9 antigen, pancreatic adenocarcinoma, pancreatic neoplasms, predictor of mortality, veteran",
author = "David Kim and Hong Zhu and Ammar Nassri and Ali Mokdad and Sachin Kukreja and Patricio Polanco and Sergio Huerta and Zeeshan Ramzan",
year = "2016",
month = "6",
day = "1",
doi = "10.1111/1751-2980.12361",
language = "English (US)",
volume = "17",
pages = "399--407",
journal = "Journal of Digestive Diseases",
issn = "1751-2972",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Survival analysis of veteran patients with pancreatic cancer

AU - Kim, David

AU - Zhu, Hong

AU - Nassri, Ammar

AU - Mokdad, Ali

AU - Kukreja, Sachin

AU - Polanco, Patricio

AU - Huerta, Sergio

AU - Ramzan, Zeeshan

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Objective: For patients with pancreatic cancer, the identification of reliable predictors of their outcomes could be invaluable for directing the managements. This study aimed to identify clinical and laboratory factors that could be used to predict early (≤6 months) or late (>6 months) mortality. Methods: Medical records of patients diagnosed with pancreatic cancer in the VA North Texas Health Care System from 2005 to 2010 were retrospectively reviewed. Univariate and multivariate analyses (MVA) were performed and the utility of cancer antigen 19-9 (CA19-9) test was explored. Results: Altogether 109 patients with pancreatic cancer, 89.0% of whom were with adenocarcinoma, were divided into early (n = 62) and late (n = 47) mortality groups. Kaplan–Meier analysis revealed a median survival of 154 days [95% confidence interval (CI) 93–194 days]. On MVA, abdominal pain (OR = 10.6, P = 0.009) and large tumor size (OR = 2.4, P = 0.028) were significantly associated with early mortality, while palliative chemotherapy (OR = 0.048, P = 0.001) and neuroendocrine tumor (OR = 0.009, P = 0.024) were significantly associated with late mortality. Subgroup analyses of adenocarcinoma and late-stage patients revealed similar results. Serum CA19-9 performed poorly as a prognostic indicator in both groups (P = 0.43), in metastatic disease at diagnosis (P = 0.32) and after treatment (P = 0.65). Conclusions: Abdominal pain and large tumor size portends a poor prognosis in patients with pancreatic cancer. Palliative chemotherapy and surgical intervention may prolong the patient's survival. CA19-9 is not universally reliable for predicting metastasis, survival, or the responses to chemotherapy.

AB - Objective: For patients with pancreatic cancer, the identification of reliable predictors of their outcomes could be invaluable for directing the managements. This study aimed to identify clinical and laboratory factors that could be used to predict early (≤6 months) or late (>6 months) mortality. Methods: Medical records of patients diagnosed with pancreatic cancer in the VA North Texas Health Care System from 2005 to 2010 were retrospectively reviewed. Univariate and multivariate analyses (MVA) were performed and the utility of cancer antigen 19-9 (CA19-9) test was explored. Results: Altogether 109 patients with pancreatic cancer, 89.0% of whom were with adenocarcinoma, were divided into early (n = 62) and late (n = 47) mortality groups. Kaplan–Meier analysis revealed a median survival of 154 days [95% confidence interval (CI) 93–194 days]. On MVA, abdominal pain (OR = 10.6, P = 0.009) and large tumor size (OR = 2.4, P = 0.028) were significantly associated with early mortality, while palliative chemotherapy (OR = 0.048, P = 0.001) and neuroendocrine tumor (OR = 0.009, P = 0.024) were significantly associated with late mortality. Subgroup analyses of adenocarcinoma and late-stage patients revealed similar results. Serum CA19-9 performed poorly as a prognostic indicator in both groups (P = 0.43), in metastatic disease at diagnosis (P = 0.32) and after treatment (P = 0.65). Conclusions: Abdominal pain and large tumor size portends a poor prognosis in patients with pancreatic cancer. Palliative chemotherapy and surgical intervention may prolong the patient's survival. CA19-9 is not universally reliable for predicting metastasis, survival, or the responses to chemotherapy.

KW - CA19-9 antigen

KW - pancreatic adenocarcinoma

KW - pancreatic neoplasms

KW - predictor of mortality

KW - veteran

UR - http://www.scopus.com/inward/record.url?scp=84983666705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983666705&partnerID=8YFLogxK

U2 - 10.1111/1751-2980.12361

DO - 10.1111/1751-2980.12361

M3 - Article

C2 - 27235863

AN - SCOPUS:84983666705

VL - 17

SP - 399

EP - 407

JO - Journal of Digestive Diseases

JF - Journal of Digestive Diseases

SN - 1751-2972

IS - 6

ER -